You are here: Industry Insights > Market News > J&J single-dose COVID-19 vaccine gets approval for EUA in India

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Constant-temperature Drying Oven

SUS304 Forced Air Drying Oven

J&J single-dose COVID-19 vaccine gets approval for EUA in India

expresspharmaAugust 09, 2021

Tag: J&J , EUA , COVID-19 , India

Favorites

“Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India,” tweeted Union Health Minister, Mansukh Mandaviya last week.

J&J single-dose COVID-19 vaccine gets approval for EUA in India

The company had applied last week for the Emergency Use Authorisation (EUA) of its single-dose COVID-19 vaccine in India.

“Now India has five EUA vaccines. This will further boost nation’s collective fight against COVID-19,” the tweet further informed.

The EUA submission is based on topline efficacy and safety data from the phase-III ENSEMBLE clinical trial, which demonstrated that the company’s single-shot vaccine was 85 per cent effective in preventing the disease across all regions studied.

Previous:Pharma cos foray into digital healthcare to bolster personalised care in India: GlobalData

Next:Government increases JAK storeowners’ incentive from Rs 2.50 lakhs to up to Rs 5 lakhs

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

PRNewswireDecember 30, 2024

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies.

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

PRNewswireDecember 30, 2024

Basecare Medical Group (2170.HK) and Jinghua Medical Group Sign Strategic Cooperation Agreement

PRNewswireDecember 27, 2024

J&J single-dose COVID-19 vaccine gets approval for EUA in India | Pharmasources.com

IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

PRNewswireDecember 27, 2024

Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033 has been approved by CDE of NMPA.

J&J single-dose COVID-19 vaccine gets approval for EUA in India

Related News

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

Basecare Medical Group (2170.HK) and Jinghua Medical Group Sign Strategic Cooperation Agreement

IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

You may like
More>>

J&J single-dose COVID-19 vaccine gets approval for EUA in India

Related News

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

Basecare Medical Group (2170.HK) and Jinghua Medical Group Sign Strategic Cooperation Agreement

IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

You may likeMore>>

You may like
More>>